Our #STOPCAP #IPDMA of #docetaxel for advanced #prostateCancer #mHSPC came out this week in #LancetOncology!
Very excited about this: result of tremendous collaborative effort to obtain harmonized trial data, apply meticulous checking & processing, and carry out high-quality statistical analysis. Aim was to clarify patterns of survival within patient subgroups most & least likely to benefit.
Day 3 of course “Statistical Methods for IPD Meta-Analysis” #ipdma
Today covers multivariate IPD meta-analysis (to pool multiple outcomes, multiple timepoints, spline functions etc) & benefits of IPD for network MA
+ special topics of diagnostic tests, missing data & PRISMA-IPD
Love the idea of #Introduction posts!
Hi I'm David, a #statistician & #methodologist at #UCL, working in #ClinicalTrials and #MetaAnalysis (MA), particularly in #oncology & with #survival data. I've been involved in large-scale #RCTs, meta-analysis of #COVID19 data on behalf of #WHO, and currently working with large-scale #IPDMA in #prostateCancer. Main methodological interest is treatment interactions with observed patient #subgroups in MA. I also write & maintain #Stata packages.
David Fisher
Richard Riley (R^2)